Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids
Shots:
- The companies collaborated to develop improved tissue-selective AAV vectors to realize effective gene therapy treatments for multiple life-threatening disorders
- The focus of this agreement is to develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency
- The collaboration comes two years after Sirion signed a similar pact with Denali Therapeutics- with other partners including Acucela and Orchard Therapeutics
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com